E
BioLineRx Ltd.
BLRX
$3.10
$0.186.16%
E
Sell
3/14/2023Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 03/14/2023.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
BioLineRx Ltd. (BLRX) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.02 to 0.17.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.02 to 0.17.
D
Sell
5/25/2022Downgrade
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 5/25/2022 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.006 to -$0.0069, the quick ratio declined from 5.89 to 5.58, and operating cash flow declined 1.51% from -$5.5M to -$5.59M.
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 5/25/2022 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.006 to -$0.0069, the quick ratio declined from 5.89 to 5.58, and operating cash flow declined 1.51% from -$5.5M to -$5.59M.
D
Sell
5/17/2022Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index and valuation index.
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/13/2022Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and valuation index.
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index and valuation index.
E
Sell
5/1/2022Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/26/2022Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 4/26/2022 due to an increase in the valuation index.
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 4/26/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 04/20/2022.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 04/20/2022.
D
Sell
4/19/2022Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 4/19/2022 due to an increase in the volatility index.
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 4/19/2022 due to an increase in the volatility index.
D
Sell
3/31/2022Downgrade
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 9.77% from -$5.01M to -$5.5M, and EBIT declined 6.13% from -$6.22M to -$6.6M.
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 3/31/2022 due to a substantial decline in the total return index, volatility index and growth index. Operating cash flow declined 9.77% from -$5.01M to -$5.5M, and EBIT declined 6.13% from -$6.22M to -$6.6M.
D
Sell
11/9/2021Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 11/09/2021.
BioLineRx Ltd. (BLRX) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
1/13/2021Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 1/13/2021 due to an increase in the total return index, volatility index and valuation index.
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 1/13/2021 due to an increase in the total return index, volatility index and valuation index.
D
Sell
12/29/2020Downgrade
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 12/29/2020 due to a decline in the volatility index and valuation index.
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 12/29/2020 due to a decline in the volatility index and valuation index.
D
Sell
12/9/2020Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 12/9/2020 due to an increase in the total return index, volatility index and growth index. Earnings per share increased from -$0.0307 to -$0.0156, EBIT increased 16.48% from -$5.57M to -$4.65M, and operating cash flow increased 1.69% from -$5.57M to -$5.47M.
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 12/9/2020 due to an increase in the total return index, volatility index and growth index. Earnings per share increased from -$0.0307 to -$0.0156, EBIT increased 16.48% from -$5.57M to -$4.65M, and operating cash flow increased 1.69% from -$5.57M to -$5.47M.
D
Sell
5/21/2020Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D- from E+ on 5/21/2020 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0624 to -$0.04, and EBIT increased 27.33% from -$9.41M to -$6.84M.
BioLineRx Ltd. (BLRX) was upgraded to D- from E+ on 5/21/2020 due to a large increase in the growth index and volatility index. Earnings per share increased from -$0.0624 to -$0.04, and EBIT increased 27.33% from -$9.41M to -$6.84M.
E
Sell
5/20/2020Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 5/20/2020 due to a noticeable decline in the growth index, efficiency index and volatility index.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 5/20/2020 due to a noticeable decline in the growth index, efficiency index and volatility index.
D
Sell
4/13/2020Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D- from E+ on 4/13/2020 due to an increase in the volatility index.
BioLineRx Ltd. (BLRX) was upgraded to D- from E+ on 4/13/2020 due to an increase in the volatility index.
E
Sell
3/27/2020Downgrade
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 3/27/2020 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0264 to -$0.0624, and EBIT declined 41.7% from -$6.64M to -$9.41M.
BioLineRx Ltd. (BLRX) was downgraded to E+ from D- on 3/27/2020 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.0264 to -$0.0624, and EBIT declined 41.7% from -$6.64M to -$9.41M.
D
Sell
7/12/2019Downgrade
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 7/12/2019 due to a decline in the valuation index, volatility index and total return index.
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 7/12/2019 due to a decline in the valuation index, volatility index and total return index.
D
Sell
6/5/2019Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 6/5/2019 due to a large increase in the growth index, solvency index and efficiency index. EBIT increased 20.73% from -$7.04M to -$5.58M, total capital increased 13.03% from $50.05M to $56.58M, and operating cash flow increased 10.1% from -$5.14M to -$4.62M.
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 6/5/2019 due to a large increase in the growth index, solvency index and efficiency index. EBIT increased 20.73% from -$7.04M to -$5.58M, total capital increased 13.03% from $50.05M to $56.58M, and operating cash flow increased 10.1% from -$5.14M to -$4.62M.
D
Sell
12/17/2018Downgrade
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 12/17/2018 due to a decline in the volatility index and total return index.
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 12/17/2018 due to a decline in the volatility index and total return index.
D
Sell
11/30/2018Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 11/30/2018 due to an increase in the volatility index.
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 11/30/2018 due to an increase in the volatility index.
D
Sell
11/15/2018Downgrade
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 11/15/2018 due to a decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0449 to -$0.059, EBIT declined 8.47% from -$5.73M to -$6.21M, and the quick ratio declined from 7.79 to 7.28.
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 11/15/2018 due to a decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0449 to -$0.059, EBIT declined 8.47% from -$5.73M to -$6.21M, and the quick ratio declined from 7.79 to 7.28.
D
Sell
10/1/2018Upgraded
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 10/1/2018 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0584 to -$0.0449, EBIT increased 13.61% from -$6.63M to -$5.73M, and operating cash flow increased 8.43% from -$6.81M to -$6.23M.
BioLineRx Ltd. (BLRX) was upgraded to D from D- on 10/1/2018 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0584 to -$0.0449, EBIT increased 13.61% from -$6.63M to -$5.73M, and operating cash flow increased 8.43% from -$6.81M to -$6.23M.
D
Sell
4/12/2018Downgrade
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 4/12/2018 due to a decline in the growth index, total return index and efficiency index. Total capital declined 10.4% from $59.3M to $53.13M, EBIT declined 8.94% from -$7.06M to -$7.69M, and operating cash flow declined 1.72% from -$6.22M to -$6.32M.
BioLineRx Ltd. (BLRX) was downgraded to D- from D on 4/12/2018 due to a decline in the growth index, total return index and efficiency index. Total capital declined 10.4% from $59.3M to $53.13M, EBIT declined 8.94% from -$7.06M to -$7.69M, and operating cash flow declined 1.72% from -$6.22M to -$6.32M.
D
Sell
8/1/2017Upgraded
BioLine Rx Ltd (BLRX) was upgraded to D from D- on 8/1/2017 due to an increase in the total return index.
BioLine Rx Ltd (BLRX) was upgraded to D from D- on 8/1/2017 due to an increase in the total return index.
D
Sell
6/15/2017Downgrade
BioLine Rx Ltd (BLRX) was downgraded to D- from D on 6/15/2017 due to a noticeable decline in the growth index, efficiency index and solvency index. The quick ratio declined from 9.79 to 5.98, EBIT declined 20.92% from -$4.38M to -$5.3M, and net income declined 13.3% from -$4.29M to -$4.86M.
BioLine Rx Ltd (BLRX) was downgraded to D- from D on 6/15/2017 due to a noticeable decline in the growth index, efficiency index and solvency index. The quick ratio declined from 9.79 to 5.98, EBIT declined 20.92% from -$4.38M to -$5.3M, and net income declined 13.3% from -$4.29M to -$4.86M.
D
Sell
5/27/2016Upgraded
BioLineRx, Ltd. (BLRX) was upgraded to D from D- on 5/27/2016 due to an increase in the efficiency index, growth index and total return index. EBIT increased 7.9% from -$4.1M to -$3.78M, earnings per share increased from -$0.0668 to -$0.0636, and net income increased 4.46% from -$3.65M to -$3.49M.
BioLineRx, Ltd. (BLRX) was upgraded to D from D- on 5/27/2016 due to an increase in the efficiency index, growth index and total return index. EBIT increased 7.9% from -$4.1M to -$3.78M, earnings per share increased from -$0.0668 to -$0.0636, and net income increased 4.46% from -$3.65M to -$3.49M.
D
Sell
3/11/2016Downgrade
BioLineRx, Ltd. (BLRX) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index and total return index.
BioLineRx, Ltd. (BLRX) was downgraded to D- from D on 3/11/2016 due to a large decline in the volatility index and total return index.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
